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Abstract
OBJECTIVE—Opioid medications are among the most effective analgesics. However, the 
consequences of opioid exposure to the developing human offspring are not known. We assessed 
whether maternal opioid use in the periconceptional period was associated with the risk of neural 
tube defects in the offspring.
METHODS—We used data from 1998 to 2010 from the Slone Epidemiology Center Birth 
Defects Study, an ongoing case–control study. Mothers were interviewed by telephone within 6 
months of delivery about sociodemographic factors and exposures during pregnancy including 
detailed questions on type and timing of medication use. Mothers of 305 offsprings with neural 
tube defect were compared with mothers of 7,125 offsprings in the nonmalformed control group 
and 13,405 offsprings in the malformed control group. Periconceptional opioid use was defined as 
any reported use in the 2 months after the last menstrual period. Logistic regression models were 
used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for study center.
RESULTS—A higher percentage of mothers of offsprings with neural tube defects (3.9%) 
reported using an opioid medication than mothers of offsprings in the nonmalformed control group 
(1.6%) and offsprings in the malformed control group (2.0%) with adjusted ORs of 2.2 (95% CI 
1.2 24.2) and 1.9 (95% CI 1.0 23.4), respectively. When offsprings were restricted to those with 
spina bifida, the adjusted ORs were 2.5 (95% CI 1.3–5.0) and 2.2 (95% CI 1.1–4.1), respectively.
CONCLUSION—A 2.2-fold increase in risk would translate to a neural tube defect prevalence of 
5.9 per 10,000 live births among women who use opioids. Overall, opioid use in the 
periconceptional period appeared to be associated with a modest increased risk of neural tube 
defects.
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Opioid medications are effective analgesics and are among the most commonly prescribed 
drugs in the United States.1–3 Estimates of the prevalence of opioid use among women of 
reproductive age range widely, from 1.5% to 23%, but exposure appears to be increasing 
over time.4–7 The prevalence of use is similar among pregnant women and ranges from 2% 
to 20%.7,8 When temporal trends of first-trimester use among pregnant women were 
examined, the prevalence more than doubled from 8.6% in 1995 to 20.1% in 2009.8
Opioids cross the placenta9 and have been detected in the umbilical cord, placenta, and 
meconium,10,11 but the effects of opioid exposure on the developing human fetus are not 
known.10,11 In animal studies, exposure to codeine, heroin, hydromorphone, meperidine, 
methadone, morphine, and propoxyphene during critical periods of gestation can lead to 
anomalies of the central nervous system.12–15 Two epidemiologic studies also suggest that 
there may be an association between opioids as a class and central nervous system 
anomalies, specifically neural tube defects, with odds ratio (ORs) ranging from 1.7 to 
2.9.7,16 Few studies had sufficient numbers of exposed cases to examine individual opioids, 
but those that have observed an increased risk of neural tube defects with codeine and 
hydrocodone.7,17
The objective of our study was to examine whether the risks of neural tube defects were 
increased among mothers with opioid use in the periconceptional period, the gestational time 
of neural tube defect development, and whether risks were higher for subgroups of opioid 
medications.
MATERIALS AND METHODS
The Birth Defects Study (also known as the Pregnancy Health Interview Study) is an 
ongoing case–control study conducted by the Slone Epidemiology Center at Boston 
University. The study began in 1976 and the methods have been previously described in 
detail.18–20 For the present analysis, cases were ascertained from birth hospitals and tertiary 
care centers in the greater metropolitan areas of Boston, Massachusetts; Philadelphia, 
Pennsylvania; Toronto, Canada; San Diego County, California; and from birth defect 
registries in Massachusetts and New York state. For the hospital-based centers, study staff 
identified cases from clinical and surgical logs, discharge lists, and newborn nurseries. The 
study has been approved by the institutional review board at Boston University and other 
institutions, as appropriate, and is in compliance with the Health Insurance Portability and 
Accountability Act. For this analysis, the data were restricted to the years 1998–2010.
Cases included liveborn offsprings, terminations, and fetal deaths after 20 weeks of 
gestation, although the latter two groups were not routinely ascertained. For the present 
analysis, cases consisted of infants with anencephaly, encephalocele, or spina bifida. 
Excluded were conjoined twins and infants affected by chromosomal anomalies, Mendelian-
inherited disorders, known syndromes, amniotic bands, or body wall defects. Offsprings in 
the case group were considered “isolated” if they had no other major structural 
malformation. Liveborn offsprings with no major malformations were selected for the 
control group (nonmalformed group) from the same birth hospitals as offsprings in the case 
group or from a random sample of statewide birth records (Massachusetts only). Telephone 
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interviews were conducted within 6 months of delivery by trained study nurses. The 
computer-assisted interview included questions on demographic information, reproductive 
history, parental occupations, behavioral factors during pregnancy (eg, cigarette smoking, 
alcohol and caffeine consumption), dietary history, illness history, and details of medication 
and vitamin use. In the medication section, mothers were specifically asked if they had taken 
any medications for “migraine,” “headache,” “backache,” “joint or muscle pain, sprains, or 
injury,” “other pains,” “any other drugs (cocaine, crack, marijuana, or any others),” and 
“other indications.” No specific prompts were used to identify use of illicit opioids (eg, 
heroin). The Slone Drug Dictionary4 was used to identify which of the medications reported 
were opioids, defined as a substance that binds to the opioid receptors in the body. Exposure 
was defined as reported use of an opioid in the periconceptional period—that is, in the two 
28-day months after the mother’s last menstrual period. Women who were uncertain of their 
exposure dates or only reported opioid use outside the periconceptional period were not 
included in the analysis.
The distribution of opioid exposures was compared between mothers of offsprings in the 
case group and those in the control group, and logistic regression models were used to 
estimate ORs and 95% confidence intervals (CIs). Sociodemographic factors that were 
considered as potential confounders included study center (Boston, Philadelphia, Toronto, 
San Diego, New York), maternal race or ethnicity (non-Hispanic white, non-Hispanic 
African American, Hispanic, Asian, other), maternal age (younger than 20, 20–24, 25–29, 
30–34, 35–39, 40 years or older), maternal education (less than 12 years, 12 years, 12 years 
or more), prepregnancy body mass index (calculated as weight (kg)/[height (m)]2; less than 
18.5, 18.5 to less than 25, 25 to less than 30, 30 or greater), pregnancy intention (intended or 
unintended), gestational diabetes (yes or no), smoking (yes or no), use of folic acid-
containing multivitamins (no use, consistent use, inconsistent use), illicit street drugs (yes or 
no), and concomitant medications for pain (yes or no). Each factor was added into the model 
one at a time and if the OR for opioid use changed by more than 10%, the factor was 
included in the final model. As a result of the small number of anencephaly and 
encephalocele cases, only spina bifida cases were assessed separately. Given previously 
reported associations with codeine, we separately considered codeine-containing products 
and noncodeine-containing opioids. The number of exposed cases was insufficient to permit 
risk estimation for specific opioids.
Case–control studies of birth defects are often thought to be subject to recall bias. This 
concern arises over suspicion that mothers with malformed offsprings may under- or 
overreport their exposures, possibly out of guilt or enhanced recall, respectively. There is 
little evidence to suggest this is the case,21 but to assess the possibility of such a bias, we 
used a second control group consisting of mothers of infants with a wide range of 
malformations other than neural tube defects. Mothers in this control group are assumed to 
have similar reporting accuracy as mothers of offsprings in the case group. All analyses 
were conducted separately for offsprings in the nonmalformed control group and offsprings 
in the malformed control group.
A sensitivity analysis was conducted in which non-neural tube defect birth defects that had 
previously been associated with opioid use were removed from the malformed control 
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group. Based on the Broussard et al study, which examined opioid use and a wide range of 
birth defects,7 birth defects with an adjusted OR greater than 1.3 were removed from the 
malformed control group for this analysis.
Two additional sensitivity analyses were performed to assess the possibility of selection 
bias. The first was prompted by the lack of an appropriate control group for cases that ended 
in terminations and the underascertainment of terminations, stillbirths, and neonatal deaths. 
In our study, terminations of offsprings with no birth defects were not ascertained. Even if 
they had been, these women would not necessarily be the optimal control group because 
women who terminate for reasons other than a birth defect may differ in various 
characteristics. Therefore, the first sensitivity analysis restricted the cases and both control 
groups to only liveborn offsprings. The second analysis was prompted by the fact that a non-
malformed offsprings in the control group could come from a study hospital from which we 
had no neural tube defect cases; in such a situation, it would be possible that the control 
population would not represent the base population that gave rise to cases, which could 
introduce selection bias. The sensitivity analysis was thus restricted to cases and 
nonmalformed controls from the same birth hospitals. All analyses were performed using 
SAS 9.1 software.
RESULTS
Of the mothers contacted by telephone, 65% of nonmalformed offsprings in the control 
group and 68% of offsprings in the case group with any major malformation provided 
consent and participated in the interview. A total of 305 offsprings with neural tube defects 
were identified, of which 220 had spina bifida, 51 had anencephaly, 30 had encephalocele, 
three had both spina bifida and encephalocele, and one had both spina bifida and 
anencephaly. The nonmalformed group and the malformed control group consisted of 7,125 
offsprings and 13,405 offsprings, respectively. Maternal demographic and behavioral 
characteristics are presented in Table 1. A small proportion of women were excluded as a 
result of uncertain dates of exposures (0.5% of offsprings in the nonmalformed control 
group and 0.6% of offsprings in the malformed control group) or reporting opioid use only 
outside the periconceptional period (4.1% of case offsprings, 4.6% of nonmalformed 
controls, and 4.7% of malformed controls). Fifteen different opioids (codeine, oxycodone, 
hydrocodone, morphine, propoxyphene, meperidine, methadone, tramadol, hydromorphone, 
butorphanol, heroin, fentanyl, buprenorphine, nalbuphine, and diphenoxylate) were reported 
as having been used in the periconceptional period exposure window. For each outcome 
group, the most commonly reported specific agents were codeine, oxycodone, and 
hydrocodone.
Maternal report of indications for opioid use in the periconceptional period varied and were 
grouped into the following categories: pain (joint or muscle pain, sprains, injury, backache, 
arthritis, cramps, menstrual problems, or other unspecified pains), headache (migraine or 
headache), infections (cold, flu, cough, bronchitis, pneumonia, sinusitis, sinus infection, 
congestion, strep throat, ear infection, stomach flu, or urinary tract infection), dental 
(toothache, tooth abscess, or dental procedure), medical procedures (gynecologic, infertility, 
hospitalization, or other unspecified medical procedures), other (allergies, asthma, seizures, 
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high blood pressure, sleeping problems, nausea and vomiting, stomach problems, vaginal 
bleeding, yeast or vaginal infections, or not otherwise specified conditions), and abuse (or its 
treatment). The last indication included reports of heroin, methadone, and buprenorphine as 
well as oxycodone and hydrocodone when the mother’s volunteered response suggested 
abuse. As a result of acetaminophen with codeine being readily available over the counter in 
Canada, some indications that are not typically treated with opioids (eg, stomach flu, yeast 
infections) were reported by mothers. The most frequently reported reason for using an 
opioid among all mothers was pain followed by headache (Table 2).
Mothers of offsprings with neural tube defects reported more opioid use during the 
periconceptional period (3.9%) than mothers of offsprings in the nonmalformed (1.6%) and 
malformed control groups (2.0%) (Table 3). The mean duration of opioid use reported by 
mothers was 87.4, 84.8, and 89.3 days for offsprings with neural tube defects, offsprings in 
the nonmalformed control group, and offsprings in the malformed control group, 
respectively. Only study center met the criterion for confounding and was included in the 
final model; of note, folic acid did not confound our associations although folic acid has 
been found to reduce the risk of spina bifida. When the nonmalformed control group was 
used, the adjusted OR for mothers who reported any opioid medication in the 
periconceptional period was 2.2 (95% CI 1.2–4.2).When the data were restricted to 
offsprings with spina bifida, the adjusted OR was 2.5 (95% CI 1.3–5.0). When opioids were 
subgrouped according to codeine or noncodeine opioids, the ORs for neural tube defects 
were not materially different, although a somewhat higher risk for spina bifida was observed 
for noncodeine opioids (OR 2.8, 95% CI 1.3–6.3). When opioid use was restricted to only 
those who reported it for pain, the most commonly reported indication for use, the estimates 
remained elevated with adjusted ORs of 2.0 (95% CI 0.8–4.8) and 2.2 (95% CI 0.9–5.7) for 
neural tube defects and spina bifida, respectively, although the CIs included 1.0. Among the 
162 offsprings with spina bifida considered isolated, mothers of seven (4.3%) reported 
opioid use in the periconceptional period, and ORs did not change substantially (data not 
shown).
The observed pattern of results held when malformed controls were used, although the 
estimates were slightly attenuated (Table 3). When previously associated nonneural tube 
defect birth defects were removed from the malformed control groups, the prevalence of 
opioid use remained the same among the malformed control group (1.9%) and adjusted 
estimates did not change substantially: 2.1 (95% CI 1.1–3.8) and 2.4 (95% CI 1.3–4.7) for 
neural tube defects and spina bifida, respectively.
When the data were restricted to only liveborn offsprings, ORs were 2.4 (95% CI 1.2–4.9) 
with the nonmalformed control group and 2.2 (95% CI 1.1–4.3) with the malformed control 
group. Odds ratios also remained elevated when offsprings in the case group and offsprings 
in the nonmalformed control group were restricted to those from the same birth hospital: 2.0 
(95% CI 1.0 24.1) and 2.4 (95% CI 1.1 25.2) for neural tube defects and spina bifida, 
respectively.
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Overall, our data support a modestly increased risk of neural tube defects associated with 
maternal periconceptional opioid use. Based on the most recent prevalence for neural tube 
defects in the United States,22 a 2.2-fold increase in risk would translate to a neural tube 
defect prevalence of 5.9 per 10,000 live births among women who use opioids.
Our results are consistent with other epidemiologic studies of this topic. The National Birth 
Defects Prevention Study also used a case–control design and reported ORs of 2.0 and 1.7 
for spina bifida and anencephaly, respectively, for first-trimester opioid use and stronger 
associations for hydrocodone but a more modest association for codeine.7 Bracken and 
colleagues16 reported an OR of 2.9 for first-trimester narcotic use and central nervous 
system anomalies, which included spina bifida. First-trimester codeine use was not 
associated with central nervous system defects17 or neural tube defects23 in two other 
studies. We observed higher estimates for codeine use, but all the studies had small numbers 
of exposed women and wide CIs. To better assess individual opioids, larger studies will be 
needed.
Animal studies showed prenatal opioid exposure can lead to central nervous system 
malformations,12 kinking of the spinal cord,13,14 a reduction in neural tube volume and 
thickness,15,24 and inhibited growth of the brain and nervous system.25,26 Furthermore, 
opioids cross the blood–brain barrier and are detectable in fetal tissue26–29 with the highest 
concentrations in the fetal nervous system.30 Endogenous opioids and opioid receptors are 
known to play a role in cell proliferation in the developing brain, organogenesis, DNA 
synthesis, and are also thought to act as a negative growth regulator.31,32 Thus, if our 
observed associations reflect causality, they may reflect an interaction of exogenous opioids 
with endogenous opioids and their receptors during development, leading to a malformation 
of the neural tube.33
There were limitations to our study. First, numbers of exposed mothers for some analyses 
were small and the resulting estimates were unstable with CIs that included 1.0. Small 
numbers also limited our ability to explore associations with specific opioids. In addition, 
we conducted multiple analyses and cannot rule out the possibility of chance associations. 
We did not have information on dosage and were not able to assess a dose response. 
Furthermore, our interview inquired about indications that frequently involve treatment with 
opioids, not specific opioids, although prompts were thorough and it is likely mothers would 
recall using an opioid when prompted with various indications.
The prevalence of periconceptional opioid use in our study was 3.9% for offsprings in the 
case group, 1.6% for offsprings in the nonmalformed control group, and 2.0% for offsprings 
in the malformed control group. Previous studies report varying prevalences of opioid use in 
early pregnancy. Broussard and colleagues7 reported first-trimester opioid use ranging from 
2% to 2.6%. Another study using Tennessee Medicaid data reported 14.5% of mothers filled 
a prescription for an opioid in their first trimester.8 Neither of these studies included illicit 
opioid use and although we included reports of opioid abuse, it is likely underreported 
because we did not explicitly ask about drug abuse.
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We cannot rule out the possibility that the observed increased risk for opioid use is the result 
of the underlying indication. However, multiple and diverse indications were reported by 
mothers, reducing the likelihood of such confounding.
Another limitation is the possibility of selection bias related to underascertainment of case 
terminations or fetal losses. Such bias is unlikely to account for our findings, because 
restricting cases and controls to liveborn offsprings did not change our results. However, if 
terminations were associated with opioid use, our results may only be generalizable to 
liveborn offsprings and not all neural tube defects. Similarly, analysis restricted to cases and 
control mothers from the same hospitals did not materially alter our findings. Selection bias 
arising from differential participation according to opioid use and case–control status is also 
a possibility. However, we would expect this differential to be between mothers with and 
without a malformed child. The similar results observed for both the nonmalformed and 
malformed control groups suggest participation bias does not account for the observed 
associations.
These assessments for possible selection bias are among our study’s strengths as was the use 
of a malformed control group to assess the possibility of recall bias. In addition, the short 
interval between delivery and interview (6 months or less) reduced concerns of incomplete 
recall. The medication information collected in the interview was detailed with respect to 
gestational timing and allowed us to identify use during the relatively narrow window for 
exposures that may affect neural tube development.
In conclusion, our findings support and extend previous research demonstrating an 
approximately twofold higher risk for neural tube defects, and particularly spina bifida, with 
maternal periconceptional opioid use.
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N (%) N (%) N (%)
Total 305 (100) 7125 (100) 13405 (100)
Maternal race/ethnicity
  White, non-Hispanic 182 (59.7) 4980 (69.9) 8576 (64.0)
  Black, non-Hispanic 35 (11.5) 556 (7.8) 1277 (9.5)
  Hispanic 60 (19.7) 1033 (14.5) 2314 (17.3)
  Asian 23 (7.5) 400 (5.6) 847 (6.3)
  Other 5 (1.6) 150 (2.1) 365 (2.7)
  Missing data 0 (0.0) 6 (0.1) 26 (0.2)
Maternal age at conception
  < 20 years 21 (6.9) 515 (7.2) 1100 (8.2)
  20–24 years 48 (15.7) 994 (14.0) 2118 (15.8)
  25–29 years 103 (33.8) 1857 (26.1) 3318 (24.8)
  30–34 years 84 (27.5) 2418 (33.9) 4056 (30.3)
  35–39 years 45 (14.8) 1149 (16.1) 2231 (16.6)
  ≥ 40 years 4 (1.3) 171 (2.4) 569 (4.2)
  Missing data 0 (0.0) 21 (0.3) 13 (0.1)
Maternal education
  < 12years 41 (13.4) 660 (9.3) 1696 (12.7)
  12 years 68 (22.3) 1294 (18.2) 2863 (21.4)
  > 12 years 196 (64.3) 5165 (72.5) 8826 (65.8)
  Missing data 0 (0.0) 6 (0.1) 20 (0.1)
Live-born
  Liveborn 205 (67.2) 7118 (99.9) 12654 (94.4)
  TAB 76 (24.9) 0 (0.0) 333 (2.5)
  Stillborn 1 (0.3) 1 (0.0) 17 (0.1)
  Neonatal death 23 (7.5) 5 (0.1) 338 (2.5)
  Infant death 0 (0.0) 1 (0.0) 63 (0.5)
Diabetes
  Gestational diabetes 16 (5.2) 327 (4.6) 854 (6.4)
  No report of gestational diabetes 289 (94.8) 6798 (95.4) 12551 (93.6)
Periconceptional vitamin use a
  No Use 88 (28.9) 1515 (21.3) 3187 (23.8)
  Consistent Use 127 (41.6) 3063 (43.0) 5321 (39.7)
  Inconsistent Use 90 (29.5) 2547 (35.7) 4897 (36.5)
Maternal smoking in the first lunar month of pregnancy
  Never / Ex-smoker 248 (81.3) 5996 (84.2) 10953 (81.7)



















N (%) N (%) N (%)
  Smoked during pregnancy 57 (18.7) 1128 (15.8) 2452 (18.3)
  Unknown 0 (0.0) 1 (0.0) 0 (0.0)
Study center
  Boston 42 (13.8) 3718 (52.2) 3266 (24.4)
  Philadelphia 99 (32.5) 1448 (20.3) 4404 (32.9)
  Toronto 90 (29.5) 649 (9.1) 2422 (18.1)
  San Diego 44 (14.4) 946 (13.3) 2094 (15.6)
  New York 30 (9.8) 364 (5.1) 1219 (9.1)
Maternal body mass index, kg/m2
  < 18.5 17 (5.6) 418 (5.9) 734 (5.5)
  18.5- < 25 155 (50.8) 4406 (61.8) 7516 (56.1)
  25- <30 65 (21.3) 1357 (19.0) 2779 (20.7)
  ≥ 30 53 (17.4) 785 (11.0) 1973 (14.7)
  Missing data 15 (4.9) 159 (2.2) 403 (3.0)
BMI, body mass index
Data are n (%)
a
Periconceptional use included the 2 lunar months before or 1 month after the last menstrual period.
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